{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T04:54:27Z","timestamp":1769835267873,"version":"3.49.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,5]],"date-time":"2021-04-05T00:00:00Z","timestamp":1617580800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,4,5]],"date-time":"2021-04-05T00:00:00Z","timestamp":1617580800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>We demonstrated that an early dysregulated cytokine response [high interleukin-10 to tissue necrosis factor (IL-10\/TNF) ratio] predicted poor outcomes in patients with <jats:italic>Staphylococcus aureus<\/jats:italic> bacteremia (SAB). However, high interpatient variability in cytokine levels were observed. We grouped cytokine measurements in quartiles and assessed their additive value to clinical variables for predicting bacterial persistence and 30-day mortality in patients with SAB.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A multicenter observational study was conducted in hospitalized patients with SAB. Medical charts were reviewed for relevant information. Blood samples were obtained for cytokine measurements by ELISA: interferon-gamma (IFN\u03b3), interleukin (IL-1\u03b2, IL-6, IL-8, IL-10, IL-17) and tissue necrosis factor (TNF). Cytokine measurements were grouped into quartiles. Significant predictors for bacterial persistence and 30-day mortality were determined by multivariable logistic regression analysis. Area under the ROC curve (AUC) analysis was performed and predictive performance was compared between models with and without cytokine quartiles.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Among 606 patients with SAB, a subset of patients (<jats:italic>n<\/jats:italic>\u2009=\u2009239) had Day 1 cytokine measurements and clinical data collected; of those, 53 (22%) had persistent bacteremia. Accounting for septic shock, the addition of either IL-10 (AUC 0.708) or TNF (AUC 0.714) quartiles measured on Day 1 improved model performance for predicting bacterial persistence. All patients had Day 4 cytokine measurements; 52 patients (8.5%) died within 30-days of SAB onset. Inclusion of either IL-10 (AUC 0.873) or TNF (AUC 0.879) quartiles, but not both, measured on Day 4 to the significant clinical predictors (coronary artery disease, Pitt bacteremia score \u2265 4, and septic shock) improved model performance for mortality.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>IL-10 or TNF levels falling within the range in the upper quartiles, when combined with clinical variables, improved model performance for predicting outcomes, and may potentially be used to support aggressive management and biomarker-guided studies to evaluate the benefit of adjunctive immunotherapy for SAB in the future.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-021-06010-0","type":"journal-article","created":{"date-parts":[[2021,4,5]],"date-time":"2021-04-05T13:03:02Z","timestamp":1617627782000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Cytokine measurements add value to clinical variables in predicting outcomes for Staphylococcus aureus bacteremia"],"prefix":"10.1186","volume":"21","author":[{"given":"Karen","family":"Tan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emi","family":"Minejima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mimi","family":"Lou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendy J.","family":"Mack","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Nieberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3302-1409","authenticated-orcid":false,"given":"Annie","family":"Wong-Beringer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,4,5]]},"reference":[{"key":"6010_CR1","doi-asserted-by":"publisher","unstructured":"van Hal SJ, Jensen SO, Vaska VL, Espedido BA, Paterson DL, Gosbell IB. Predictors of mortality in Staphylococcus aureus bacteremia. Clin Microbiol Rev. 2012;25(2):362\u201386. https:\/\/doi.org\/10.1128\/CMR.05022-11.","DOI":"10.1128\/CMR.05022-11"},{"key":"6010_CR2","doi-asserted-by":"publisher","unstructured":"Minejima E, Mai N, Bui N, Mert M, She RC, Nieberg P, et al. Defining the breakpoint duration of Staphylococcus aureus bacteremia predictive of poor outcomes. Clin Infect Dis. 2020;70(4):566\u201373. https:\/\/doi.org\/10.1093\/cid\/ciz257.","DOI":"10.1093\/cid\/ciz257"},{"key":"6010_CR3","doi-asserted-by":"publisher","unstructured":"Chong YP, Park SJ, Kim HS, Kim ES, Kim MN, Park KH, et al. Persistent Staphylococcus aureus bacteremia: a prospective analysis of risk factors, outcomes, and microbiologic and genotypic characteristics of isolates. Medicine (Baltimore). 2013;92(2):98\u2013108. https:\/\/doi.org\/10.1097\/MD.0b013e318289ff1e.","DOI":"10.1097\/MD.0b013e318289ff1e"},{"key":"6010_CR4","doi-asserted-by":"publisher","unstructured":"Volk CF, Burgdorf S, Edwardson G, Nizet V, Sakoulas G, Rose WE. IL-1\u03b2 and IL-10 host responses in patients with Staphylococcus aureus bacteremia determined by antimicrobial therapy. Clin Infect Dis. 2020;70(12):2634\u201340. https:\/\/doi.org\/10.1093\/cid\/ciz686.","DOI":"10.1093\/cid\/ciz686"},{"issue":"4","key":"6010_CR5","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1097\/CCM.0000000000001465","volume":"44","author":"E Minejima","year":"2016","unstructured":"Minejima E, Bensman J, She RC, Mack WJ, Tuan Tran M, Ny P, et al. A Dysregulated balance of Proinflammatory and anti-inflammatory host cytokine response early during therapy predicts persistence and mortality in Staphylococcus aureus bacteremia. Crit Care Med. 2016;44(4):671\u20139. https:\/\/doi.org\/10.1097\/CCM.0000000000001465.","journal-title":"Crit Care Med"},{"issue":"9","key":"6010_CR6","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1093\/cid\/ciy739","volume":"68","author":"AO Guimaraes","year":"2019","unstructured":"Guimaraes AO, Cao Y, Hong K, Mayba O, Peck MC, Gutierrez J, et al. A prognostic model of persistent bacteremia and mortality in complicated Staphylococcus aureus bloodstream infection. Clin Infect Dis. 2019;68(9):1502\u201311. https:\/\/doi.org\/10.1093\/cid\/ciy739.","journal-title":"Clin Infect Dis"},{"issue":"10","key":"6010_CR7","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1093\/cid\/cix157","volume":"64","author":"WE Rose","year":"2017","unstructured":"Rose WE, Shukla SK, Berti AD, Hayney MS, Henriquez KM, Ranzoni A, et al. Increased endovascular Staphylococcus aureus inoculum is the link between elevated serum interleukin 10 concentrations and mortality in patients with bacteremia. Clin Infect Dis. 2017;64(10):1406\u201312. https:\/\/doi.org\/10.1093\/cid\/cix157.","journal-title":"Clin Infect Dis"},{"key":"6010_CR8","unstructured":"Salas DE, Minejima E, Wu J, Fang C, Wang J, She R, Nieberg P, Wong-Beringer A. Staphylococcus aureus Bacteremia in patients not meeting sepsis criteria: clinical features, host immune response and outcomes. J Clin Med Ther. 2017;2(4):27."},{"issue":"10","key":"6010_CR9","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1093\/infdis\/jis552","volume":"206","author":"WE Rose","year":"2012","unstructured":"Rose WE, Eickhoff JC, Shukla SK, Pantrangi M, Rooijakkers S, Cosgrove SE, et al. Elevated serum interleukin-10 at time of hospital admission is predictive of mortality in patients with Staphylococcus aureus bacteremia. J Infect Dis. 2012;206(10):1604\u201311. https:\/\/doi.org\/10.1093\/infdis\/jis552.","journal-title":"J Infect Dis"},{"issue":"1","key":"6010_CR10","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/s12879-019-3770-4","volume":"19","author":"E Minejima","year":"2019","unstructured":"Minejima E, Delayo V, Lou M, Ny P, Nieberg P, She RC, et al. Utility of qSOFA score in identifying patients at risk for poor outcome in Staphylococcus aureus bacteremia. BMC Infect Dis. 2019;19(1):149. https:\/\/doi.org\/10.1186\/s12879-019-3770-4.","journal-title":"BMC Infect Dis"},{"issue":"2","key":"6010_CR11","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1086\/524667","volume":"46","author":"A Soriano","year":"2008","unstructured":"Soriano A, Marco F, Mart\u00ednez JA, Pisos E, Almela M, Dimova VP, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis. 2008;46(2):193\u2013200. https:\/\/doi.org\/10.1086\/524667.","journal-title":"Clin Infect Dis"},{"key":"6010_CR12","doi-asserted-by":"publisher","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","volume":"95","author":"PA Harris","year":"2019","unstructured":"Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L, et al. The REDCap consortium: Building an international community of software platform partners. J Biomed Inform. 2019;95:103208. https:\/\/doi.org\/10.1016\/j.jbi.2019.103208.","journal-title":"J Biomed Inform"},{"issue":"2","key":"6010_CR13","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377\u201381. https:\/\/doi.org\/10.1016\/j.jbi.2008.08.010.","journal-title":"J Biomed Inform"},{"issue":"1","key":"6010_CR14","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1186\/s12879-014-0580-6","volume":"14","author":"S McNicholas","year":"2014","unstructured":"McNicholas S, Talento AF, O'Gorman J, Hannan MM, Lynch M, Greene CM, et al. Cytokine responses to Staphylococcus aureus bloodstream infection differ between patient cohorts that have different clinical courses of infection. BMC Infect Dis. 2014;14(1):580. https:\/\/doi.org\/10.1186\/s12879-014-0580-6.","journal-title":"BMC Infect Dis"},{"issue":"1","key":"6010_CR15","doi-asserted-by":"publisher","first-page":"13995","DOI":"10.1038\/s41598-018-32275-8","volume":"8","author":"H Matsumoto","year":"2018","unstructured":"Matsumoto H, Ogura H, Shimizu K, Ikeda M, Hirose T, Matsuura H, et al. The clinical importance of a cytokine network in the acute phase of sepsis. Sci Rep. 2018;8(1):13995. https:\/\/doi.org\/10.1038\/s41598-018-32275-8.","journal-title":"Sci Rep"},{"issue":"1","key":"6010_CR16","doi-asserted-by":"publisher","first-page":"11355","DOI":"10.1038\/srep11355","volume":"5","author":"M Surbatovic","year":"2015","unstructured":"Surbatovic M, Popovic N, Vojvodic D, Milosevic I, Acimovic G, Stojicic M, et al. Cytokine profile in severe gram-positive and gram-negative abdominal sepsis. Sci Rep. 2015;5(1):11355. https:\/\/doi.org\/10.1038\/srep11355.","journal-title":"Sci Rep"},{"issue":"7","key":"6010_CR17","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1128\/AAC.43.7.1747","volume":"43","author":"MW Climo","year":"1999","unstructured":"Climo MW, Patron RL, Archer GL. Combinations of vancomycin and beta-lactams are synergistic against staphylococci with reduced susceptibilities to vancomycin. Antimicrob Agents Chemother. 1999;43(7):1747\u201353. https:\/\/doi.org\/10.1128\/AAC.43.7.1747.","journal-title":"Antimicrob Agents Chemother"},{"key":"6010_CR18","doi-asserted-by":"publisher","unstructured":"Tran KN, Rybak MJ. \u03b2-Lactam Combinations with Vancomycin Show Synergistic Activity against Vancomycin-Susceptible Staphylococcus aureus, Vancomycin-Intermediate S. aureus (VISA), and Heterogeneous VISA. Antimicrob Agents Chemother. 2018;62(6):e00157\u201318. https:\/\/doi.org\/10.1128\/AAC.00157-18.","DOI":"10.1128\/AAC.00157-18"},{"issue":"3","key":"6010_CR19","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1128\/JCM.01779-15","volume":"54","author":"CL Sy","year":"2016","unstructured":"Sy CL, Huang TS, Chen CS, Chen YS, Tsai HC, Wann SR, et al. Synergy of beta-lactams with Vancomycin against methicillin-resistant Staphylococcus aureus: correlation of disk diffusion and checkerboard methods. J Clin Microbiol. 2016;54(3):565\u20138. https:\/\/doi.org\/10.1128\/JCM.01779-15.","journal-title":"J Clin Microbiol"},{"issue":"11","key":"6010_CR20","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1002\/phar.2034","volume":"37","author":"AM Casapao","year":"2017","unstructured":"Casapao AM, Jacobs DM, Bowers DR, Beyda ND, Dilworth TJ, Group R-IS. Early Administration of Adjuvant beta-lactam therapy in combination with Vancomycin among patients with methicillin-resistant Staphylococcus aureus bloodstream infection: a retrospective, Multicenter Analysis. Pharmacotherapy. 2017;37(11):1347\u201356. https:\/\/doi.org\/10.1002\/phar.2034.","journal-title":"Pharmacotherapy"},{"key":"6010_CR21","doi-asserted-by":"publisher","unstructured":"Dilworth TJ, Casapao AM, Ibrahim OM, Jacobs DM, Bowers DR, Beyda ND, Mercier RC. Adjuvant \u03b2-Lactam Therapy Combined with Vancomycin for Methicillin-Resistant Staphylococcus aureus Bacteremia: Does \u03b2-Lactam Class Matter? Antimicrob Agents Chemother. 2019;63(3):e02211\u201318. https:\/\/doi.org\/10.1128\/AAC.02211-18.","DOI":"10.1128\/AAC.02211-18"},{"key":"6010_CR22","doi-asserted-by":"publisher","unstructured":"Davis JS, Sud A, O'Sullivan MVN, Robinson JO, Ferguson PE, Foo H, et al. Combination of Vancomycin and beta-lactam therapy for methicillin-resistant Staphylococcus aureus bacteremia: a pilot multicenter randomized controlled trial. Clin Infect Dis. 2016;62(2):173\u201380. https:\/\/doi.org\/10.1093\/cid\/civ808.","DOI":"10.1093\/cid\/civ808"},{"key":"6010_CR23","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.3389\/fimmu.2018.01926","volume":"9","author":"AM Peters van Ton","year":"2018","unstructured":"Peters van Ton AM, Kox M, Abdo WF, Pickkers P. Precision Immunotherapy for Sepsis. Front Immunol. 2018;9:1926. https:\/\/doi.org\/10.3389\/fimmu.2018.01926.","journal-title":"Front Immunol"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-06010-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-021-06010-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-06010-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,5]],"date-time":"2021-04-05T13:03:11Z","timestamp":1617627791000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-021-06010-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,5]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["6010"],"URL":"https:\/\/doi.org\/10.1186\/s12879-021-06010-0","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,5]]},"assertion":[{"value":"4 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by institutional review boards at Huntington Hospital (Pasadena, CA, USA), Los Angeles County + University of Southern California (USC) Medical Center (Los Angeles, CA, USA), and Keck Hospital of USC (Los Angeles, CA, USA). Informed consent was waived by all three participating sites, as this was an observational study. All methods were carried out in accordance with guidelines set by each institution.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no conflict of interest to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"317"}}